Drug Profile

CB 106

Alternative Names: CB-106; Coronavirus vaccine - Chimeron Bio; COVID-2019 vaccine - Chimeron Bio

Latest Information Update: 28 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
21 Mar 2022 Chimeron Bio enters into a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases for CB 106 in COVID-2019 infections
28 May 2020 Chimeron Bio and the National Center for Biodefense and Infectious Diseases agree to co-develop coronavirus vaccine for COVID-2019 infections

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com